LOI to purchase 10 million doses of China’s Zhifei vaccine now signed by MYEG

A letter of intent (LOI) has been signed by MY E.G. Services Bhd for the procurement of 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s Covid-19 vaccine in efforts to secure delivery as early as August.

MYEG said during a filing with Bursa Malaysia that it has the exclusive authority to distribute the vaccine within Malaysia for three years while through a separate partnership. Whereas, it has two-year exclusive rights to distribute vaccine in the Philippines while currently holding negotiations with other countries for the exclusive rights.

Related Posts

It has been announced last week that MYEG has plans to roll out a vaccination program in the Philippines which will encompass both the public health and private sales sectors in terms of the vaccine provision.

The LOI is for the purpose of making sure to reserve the corresponding quantity of Zhifei’s recombinant protein subunit vaccine and get it delivered by August in the event that vaccination through the private market has been enabled.

According to it, this ushers the importation of the vaccines, making it available to Malaysians as soon as the private market begins while being subject to the National Pharmaceutical Regulatory Agency’s conditional authorization of the vaccine.

The pricing will be decided later which is also subject to the conditional authorization by NPRA.

MYEG has expressed its confidence saying that once the Zhifei vaccine becomes locally available, it can play a significant role in propelling Malaysia toward achieving the herd immunity.

This vaccine which has been developed together by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences rose to be among the preferred vaccines in China after acquiring emergency use authorization in March, taking into consideration its essential attribute as a recombinant protein subunit vaccine. Over 60 million vaccine doses have been administered in provincial-level regions including Beijing. The vaccine is also being administered even in Uzbekistan.

Recombinant protein technology has been proven, as it is being used for the development of vaccines such as hepatitis B and shingles. Aside from that, producing recombinant protein vaccines at a large-scale is easier as production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.

Katherine S

1/4 German, 3/4 Malaysian. I write, follow and monitor closely political news happening in Malaysia, and other happening news in the ASEAN region. Newswriter for the best ASEAN news website - The Asian Affairs.

Recent Posts

V Surprises ARMY with Two Holiday Releases: A Festive Collab with Park Hyo-shin and “White Christmas” Cover

For K-pop fans, the Christmas season this year has become even more magical as several of their preferred stars reveal…

November 22, 2024

Celine Names TWS as Global Ambassadors Following Suzy Bae Announcement

After Suzy Bae's nomination as Celine's worldwide ambassador, the venerable French luxury fashion company has taken another bold step choosing…

November 22, 2024

Reddit Faces Widespread Outage, Users Turn to Workarounds Amid ‘Server Error’ Messages

Thousands of users of the well-known social network Reddit were left without access after a major outage of the website.…

November 22, 2024

Anne Hathaway Casted as ‘Verity’ in Colleen Hoover’s Book Adaptation

Anne Hathaway is slated to play the much expected film version of Colleen Hoover's best-selling book Verity in front of…

November 21, 2024

Gucci Set to Revolutionize Fashion Presentations with Unified Shows in 2025 under Sabato De Sarno’s Vision

Gucci is ready to change its presentation approach for 2025 in a radical action aimed to revolutionize the fashion industry.…

November 21, 2024

South Korea’s “Korea Discount”: Addressing the Governance Gap to Boost Market Value

As world investors wait for significant changes that might solve long-standing problems of governance and responsibility in South Korea's companies,…

November 21, 2024

This website uses cookies.

Read More